Vendor, Los Angeles, CA
Essential Access Health
UEI KNVJQY9UH316, CAGE 335K4
6 awards and $7,216 obligated between February 8, 2024 and August 27, 2026, 100% under full and open competition, against 15.3 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $20,779 |
| Professional, Scientific, and Technical ServicesNAICS 541712 | -$13,562 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 6 |
| Delivery Order | 5 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N94020F00001Delivery Order, June 20, 2024, Full and Open Competition, 18 offers | National Institutes of Health NichdNational Institutes of Health | Core Function ActivitiesNAICS 541714, PSC AN12 | $20,779 |
| 75N94023F00001Delivery Order, September 26, 2024, Full and Open Competition, 15 offers | National Institutes of Health NichdNational Institutes of Health | Ovaprene Phase 1: Protocol Finalization, Regulatory Approval, Start-Up, and Commencement of Recruitment, Screening, and Enrollment for the ONAICS 541714, PSC AN12 | $0 |
| 75N94020D00015July 22, 2026, Full and Open Competition, 18 offers | National Institutes of Health NichdNational Institutes of Health | Eo 14398 -To Conduct Phase I, Ii, III or IV Contraceptive Trials in Women, Treatment Trials of Gynecologic Conditions Such as Endometriosis NAICS 541714, PSC AN12 | $0 |
| HHSN27500003Delivery Order, August 27, 2026, Full and Open Competition, 1 offers | National Institutes of Health NichdNational Institutes of Health | Nichd: R&d: Clinical Evaluation of Novel Products for Female Contraception, Main Study: Non-SeverableNAICS 541712, PSC AN11 | -$0 |
| HHSN27500002Delivery Order, November 4, 2024, Full and Open Competition, 20 offers | National Institutes of Health NichdNational Institutes of Health | A Multi-Center, Randomized Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Contraceptive Efficacy and Safety of Daily OraNAICS 541712, PSC AN11 | -$5,655 |
| HHSN27500001Delivery Order, February 8, 2024, Full and Open Competition, 20 offers | National Institutes of Health NichdNational Institutes of Health | Core Function ActivitiesNAICS 541712, PSC AN11 | -$7,907 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied ResearchAN11 Health R&D Services; Health Care Services; Basic Research
- Transactions
- 10 across 6 awards